Clinical Trial Update: Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating camrelizumab plus apatinib mesylate and short-course chemotherapy for advanced esophageal cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Apatinib Mesylate (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: Esophageal Cancer by AJCC V8 Stage | Phase 2 | Status: RECRUITING